Capital Fund Management S.A. Sells 61,615 Shares of Exelixis, Inc. $EXEL

Key Points

• Capital Fund Management S.A. reduced its stake in Exelixis, Inc. by 18.8%, holding 265,966 shares worth $9.8 million after selling 61,615 shares in the first quarter.
• Exelixis reported earnings of $0.75 EPS for the last quarter, exceeding expectations, although revenue declined 10.8% year-over-year.
• Analysts have mixed ratings on Exelixis, with the current consensus rating being "Moderate Buy" and an average price target of $44.06.

Capital Fund Management S.A. decreased its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 18.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 265,966 shares of the biotechnology company's stock after selling 61,615 shares during the quarter. Capital Fund Management S.A. owned approximately 0.10% of Exelixis worth $9,819,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in EXEL. Fuller & Thaler Asset Management Inc. increased its holdings in Exelixis by 2.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company's stock worth $287,794,000 after acquiring an additional 164,134 shares in the last quarter. Invesco Ltd. boosted its position in shares of Exelixis by 40.2% in the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company's stock worth $205,725,000 after purchasing an additional 1,596,948 shares during the period. AQR Capital Management LLC increased its stake in shares of Exelixis by 25.7% in the fourth quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock worth $132,101,000 after purchasing an additional 810,857 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Exelixis in the first quarter worth $123,310,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Exelixis by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company's stock valued at $122,626,000 after purchasing an additional 69,054 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Trading Down 1.9%

EXEL traded down $0.73 during trading hours on Monday, hitting $37.90. The company's stock had a trading volume of 1,548,765 shares, compared to its average volume of 3,034,964. The stock has a market cap of $10.20 billion, a price-to-earnings ratio of 18.22, a P/E/G ratio of 0.80 and a beta of 0.29. The business's 50-day moving average price is $41.56 and its 200-day moving average price is $39.36. Exelixis, Inc. has a 12 month low of $25.12 and a 12 month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $568.26 million during the quarter, compared to analysts' expectations of $574.36 million. During the same period last year, the company posted $0.84 EPS. The business's revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Activity

In other news, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the transaction, the director owned 358,882 shares in the company, valued at approximately $15,464,225.38. The trade was a 2.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sue Gail Eckhardt sold 18,838 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $42.74, for a total value of $805,136.12. Following the transaction, the director directly owned 21,380 shares in the company, valued at approximately $913,781.20. This represents a 46.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.85% of the company's stock.

Analysts Set New Price Targets

EXEL has been the subject of several recent analyst reports. Jefferies Financial Group set a $50.00 target price on shares of Exelixis and gave the stock a "buy" rating in a report on Tuesday, June 24th. Wall Street Zen lowered Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 2nd. UBS Group set a $38.00 target price on Exelixis and gave the stock a "neutral" rating in a research report on Wednesday, July 30th. Truist Financial lowered their price target on Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, July 29th. Finally, Bank of America increased their price objective on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a report on Thursday, June 5th. Thirteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $44.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.